Researchers at University of Virginia cracked a tough nut in small-molecule GLP-1 receptor agonists,a weight loss drug class including FDA-approved orforglipron. These oral drugs struggle to bind in rodents,making lab studies hard.
Using a novel method,scientists gene-edited mice to have human-like GLP-1 receptors. This leap was needed as rodent models hit wall in studying these drugs. Published in Nature on May 6, the study shows drugs activate unexpected brain circuits tied to cravings .
Unlike injectable GLP-1 drugs like semaglutide,small-molecules have a knack for binding only to human receptors . This specificity hampered understanding in animal tests. Yet, the humanized mice kept normal metabolism, allowing tests of orforglipron and danuglipron.
Upon dosing these drugs, researchers tracked brain activity and found they lit up not just hypothalamic and hindbrain networks,but also neurons in the central amygdala . This region links to desire and reward, cutting down on tasty food intake by suppressing dopamine in the brain's reward center.
Ali Güler,biology professor and study co-author, noted that these drugs curb pleasure-eating by hitting this reward circuit. Findings hint at broader uses beyond obesity, maybe even affecting substance use and binge eating .
Two more tests showed the central amygdala's role in pleasure-eating. Stimulating neurons in this area reduced pleasure-eating, while removing GLP-1 receptors there weakened the drugs' effects on reward-driven eating. This points to a complex brain-reward and GLP-1 interaction.
Study hints at more than weight loss. Authors suggested reduced dopamine during pleasure-eating might affect cravings beyond food,like alcohol, a hot topic in early clinical work.
Yet,the study falls short on proving GLP-1 drugs cut cravings or treat addiction in humans. The humanized mouse model,though smart, has its limits. Neurons and circuits are still mouse-like,leaving human behavior translation uncertain. It doesn't confirm GLP-1 drugs' effectiveness on human addiction or cravings .
Orforglipron got U.S . approval, with weight and blood sugar effects proven in human trials. Patients should trust clinical evidence and doctor advice,not just this animal study.
This research sets stage for more work on small-molecule GLP-1 drugs, which were tough to study in animals. Humanized mice insights may lead to future studies on these drugs' mechanisms and uses for obesity and related disorders.
